Track Arcutis Biotherapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Arcutis Biotherapeutics, Inc. ARQT · Stock Open Arcutis Biotherapeutics, Inc. in new tab

28.26 USD
P/E
122.87
EPS
0.23
P/B
14.60
ROE
14.88
Beta
1.63
Target Price
40.38 USD
Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Arcutis Biotherapeutics reported robust Q3 2025 results, with net product revenues of $99.2 million, reflecting a substantial 122% year-over-year increase driven by strong demand for its ZORYVE portfolio.

  • Net product revenues increased 22% sequentially and 122% compared to Q3 2024, fueled by growing prescription volumes across ZORYVE formulations.
  • Total prescriptions for ZORYVE rose 13% from Q2 and 92% year-over-year, reaching record weekly averages with over 17,000 scripts.
  • The recent launch of ZORYVE cream 0.05% for atopic dermatitis (ages 2-5) is expected to further drive sales in the upcoming quarter.
  • R&D expenses remain stable year-over-year at $19.6 million, with anticipated increases in 2026 for further clinical developments.
  • Arcutis is nearing cash flow positivity, enabling sustained business investments and growth in the dermatology sector.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E122.87
EPS0.23
Book Value1.94
Price to Book14.60
Debt/Equity50.75
% Insiders6.157%
Growth
Revenue Growth0.45%
Earnings Growth0.03%
Estimates
Forward P/E25.82
Forward EPS1.09
Target Mean Price40.38

DCF valuation

Model fair value for Arcutis Biotherapeutics, Inc. (ARQT)
Result
Sign in to run the valuation for ARQT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Strong buy · mean target 40.38 USD (low 34.00, high 48.00) · as of 14 Nov 2026
Low 34.00
Mean 40.38
High 48.00
Price 28.26
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Arcutis Biotherapeutics, Inc. Logo Arcutis Biotherapeutics, Inc. Analysis (ARQT)

United States Health Care Official Website Stock

Is Arcutis Biotherapeutics, Inc. a good investment? Arcutis Biotherapeutics, Inc. (ARQT) is currently trading at 28.26 USD. Market analysts have a consensus price target of 40.38 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 122.87. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Arcutis Biotherapeutics, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 1.09.

Investor FAQ

Does Arcutis Biotherapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Arcutis Biotherapeutics, Inc.?

Arcutis Biotherapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 0.23.

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Exchange Ticker
NMS (United States) ARQT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion